Back to top
more

Editas Medicine (EDIT)

(Delayed Data from NSDQ)

$3.51 USD

3.51
1,941,434

-0.08 (-2.23%)

Updated Sep 9, 2024 04:00 PM ET

After-Market: $3.52 +0.01 (0.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Editas Medicine (EDIT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 11.54% and -3.82%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Editas Medicine (EDIT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.

Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas Medicine (EDIT) Catches Eye: Stock Jumps 9%

by Zacks Equity Research

Editas Medicine (EDIT) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

Editas, Allergan Start Dosing in Early-Stage Eye Disease Study

by Zacks Equity Research

Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.

Editas (EDIT) Q4 Earnings & Sales Fall Shy of Estimates

by Zacks Equity Research

Editas (EDIT) misses on earnings and revenues in fourth-quarter 2019.

Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of -311.43% and -75.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Editas (EDIT) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Editas (EDIT) stock based on the movements in the options market lately.

Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101

by Zacks Equity Research

Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.

Editas Medicine (EDIT) Is Up 6.66% in One Week: What You Should Know

by Zacks Equity Research

Does Editas Medicine (EDIT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Why Is Editas (EDIT) Up 28.7% Since Last Earnings Report?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher

by Zacks Equity Research

Editas Medicine (EDIT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data

by Zacks Equity Research

Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.

Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal

by Zacks Equity Research

Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 9.59% and -6.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moving Average Crossover Alert: Editas Medicine

by Zacks Equity Research

Editas Medicine, Inc. (EDIT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Editas Inks Deal for Gene Editing Neurological Disease Drugs

by Zacks Equity Research

Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.

CRISPR Therapeutics Enters New License Agreement, Shares Up

by Zacks Equity Research

CRISPR Therapeutics (CRSP) looks to strengthen its CAR-T therapy programs through its agreement with KSQ Therapeutics.

Adverum Reports Data From Phase I Wet AMD Study, Stock Down

by Zacks Equity Research

Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.

Sweta Jaiswal, FRM headshot

ETFs Poised to Benefit from Gene Editing Revolution

by Sweta Jaiswal, FRM

Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.

Why Is Editas (EDIT) Down 5.5% Since Last Earnings Report?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO

by Zacks Equity Research

In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.

Editas Medicine (EDIT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of -16.95% and -61.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?